Interview with Dr. Aaron Kesselheim on the challenges of bringing follow-on biologic drugs to the market. (12:27)Download Thanks to a new regulatory pathway created by the 2010 Biologics Price Competition and Innovation Act, the FDA has now approved its first biosimilar drug, filgrastim-sndz. The challenges to achieving savings from follow-on biologics are large but not insurmountable.
No takes yet. Share an insight, caveat, or question.
Sarpatwari et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: